Overview

Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial

Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
ACT is a randomized clinical trial to assess therapies to reduce the clinical progression of COVID-19.
Phase:
Phase 3
Details
Lead Sponsor:
Population Health Research Institute
Collaborator:
Bayer
Treatments:
Aspirin
Chloroquine
Chloroquine diphosphate
Colchicine
Interferon-beta
Interferons
Rivaroxaban